A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

Status:
Completed

Trial end date:
2012-10-01

Target enrollment:

Participant gender:

This phase I trial is studying the safety and best dose of GC33 in patients with advanced or metastatic liver cancer.

Phase 1

Chugai Pharmaceutical